drugset / Trial / NCT07499154

Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery

NCT07499154

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Cardiopulmonary bypass-associated pulmonary injury is a common complication after infant cardiac surgery and may contribute to impaired oxygenation, prolonged mechanical ventilation, and longer intensive care stay. Lidocaine has anti-inflammatory and membrane-stabilizing properties and may attenuate perioperative lung injury. This investigator-initiated, randomized, placebo-controlled, double-blind trial will evaluate whether perioperative intravenous lidocaine reduces postoperative pulmonary injury in infants undergoing corrective non-palliative congenital cardiac surgery with cardiopulmonary bypass.

Timeline

Start
2026-04-01
Primary completion
2027-12-01
Completion
2027-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 1 mg/kg Intravenous